Open-label trial of ranolazine for the treatment of myotonia congenita

Conclusions:
Ranolazine appeared to be well tolerated over a period of 4 weeks in individuals with MC, and ranolazine resulted in improvement of signs and symptoms of muscle stiffness. The findings of this study suggest that ranolazine should be investigated in a larger controlled study.

Classification of evidence:
This study provides Class IV evidence that ranolazine improves myotonia in myotonia congenita.

Source: Neurology - August 14, 2017 Category: Neurology Authors: Arnold, W. D., Kline, D., Sanderson, A., Hawash, A. A., Bartlett, A., Novak, K. R., Rich, M. M., Kissel, J. T. Tags: All Neuromuscular Disease, Muscle disease, EMG, Ion channel gene defects ARTICLE Source Type: research